Your session is about to expire
← Back to Search
BNP Hormone for Obesity (MENP Trial)
MENP Trial Summary
This trial will study whether the hormone BNP can increase energy expenditure and help with obesity.
MENP Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MENP Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are allergic to the study drug nesiritide or phenylephrine.You have serious problems with your lungs, liver, or kidneys.You are currently taking medications that can affect your blood sugar levels, like metformin.You are currently taking medications that affect your energy levels or amphetamines.You have severe fear of enclosed spaces that would make it difficult for you to use the metabolic cart as part of the study.You have a serious heart condition, such as heart failure or atrial fibrillation.You are currently taking or have recently taken glucocorticoids.
- Group 1: BNP, then placebo
- Group 2: Placebo, then BNP
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do individuals aged sixty and older meet the criteria for participating in this experiment?
"As can be inferred from the criteria for selection, only individuals between 18 and 40 years of age are eligible to partake in this study."
To whom is this research opportunity available?
"This medical trial is taking on 14 participants with obesity that range in age between 18 and 40. The essential requirements for inclusion are: Male and female aged 18-40 years, BMI scores of 18.5 - 25 kg/m2 (lean) or 30kg/m2 (obese)."
Is enrollment still available for this investigation?
"The research initiative is not currently seeking further enrolment. Initially posted on July 1st 2018 and last edited March 23rd 2022, interested parties must look elsewhere for involvement opportunities. Currently, 966 studies are actively recruiting patients with obesity while 3 investigations are looking for volunteers to partake in trials related to recombinant human BNP (1-32)."
Can you provide a comprehensive overview of prior trials related to recombinant human BNP (1-32)?
"Currently, three clinical trials are investigating recombinant human BNP (1-32). None of these live studies have achieved a Phase 3 status. Notably, the majority of research is conducted in Nashville, Tennessee; yet there are 6 medical centres running similar tests across the country."
Has recombinant human BNP (1-32) achieved regulatory approval?
"Recombinant human BNP (1-32) has achieved a safety score of 3, which is attributed to its status as an approved Phase 4 medication."
What is the scope of the population being observed in this clinical experiment?
"At present, recruitment for this clinical trial is not happening. It was initially posted July 1st 2018 and updated last on March 23rd 2022. For those looking to get involved in medical research, there are currently 966 active trials involving obesity and 3 recruiting patients for recombinant human BNP (1-32)."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger